Immutep Phase II Trial Insights on Efti in Sarcoma Therapy
Immutep Limited (ASX: IMM; NASDAQ: IMMP), an innovative biotechnology firm focused on immunotherapy for cancer and autoimmune conditions, has exciting news! Their Phase II clinical trial, EFTISARC-NEO, has been accepted for oral presentation at the prestigious Connective Tissue Oncology Society (CTOS) Annual Meeting set for November. This presentation will showcase crucial data about using eftilagimod alpha (efti) in combination with radiotherapy and KEYTRUDA for treating soft tissue sarcoma (STS).
Highlights of the Presentation
The oral presentation, featuring the title 'Primary endpoint and translational correlates from EFTISARC-NEO: phase II trial of neoadjuvant eftilagimod alpha (efti), pembrolizumab, and radiotherapy in patients with resectable soft tissue sarcoma,' is scheduled for November 13. Presented by Dr. Pawel Sobczuk from the Maria Sklodowska-Curie National Research Institute of Oncology, this session categorizes new advancements in treatments for STS, focusing on immunotherapy’s role.
Key Details of the Presentation
The details of the session include:
- Session: Immunotherapy & Cell Therapy in Sarcoma: Emerging Frontiers
- Presenter: Dr. Pawel Sobczuk
- Date & Time: November 13, from 1:30 PM to 3:00 PM ET
- Format: Oral Presentation
Understanding Soft Tissue Sarcoma
Soft tissue sarcoma, which arises from connective tissues, presents a considerable challenge in oncology due to its rarity and complex treatment requirements. In 2025, the American Cancer Society estimates around 13,520 new cases in the United States alone.
The necessity for innovative treatments like those being researched by Immutep becomes acute, with many patients facing minimal options for effective care. With the EFTISARC-NEO trial, the combination of eftilagimod alpha alongside other treatments aims to enhance the outcomes for patients suffering from STS.
Trial Funding and Support
The clinical trial is primarily funded by a grant from the Polish government through the Polish Medical Research Agency program, demonstrating governmental support for cancer research and highlighting its importance in the fight against STS.
Future Directions for Immutep
Immutep is devoted to harnessing LAG-3's potential, driving forward its quest for developing novel immunotherapy options for various chronic conditions. The EFTISARC-NEO’s promising results could pave the way for future studies and expanded applications of efti across different types of cancers.
After the CTOS Annual Meeting, the presentation slides will be available on the Posters & Publications section of Immutep’s website, ensuring access to cutting-edge findings.
About Immutep Limited
Immutep is at the forefront of developing innovative therapies that target immune response mechanisms to fight cancer and autoimmune diseases. Its product lineup prioritizes therapies focusing on LAG-3, designed to either amplify or down-regulate immune responses, amplifying its commitment to improving patient outcomes.
Frequently Asked Questions
What is the aim of the EFTISARC-NEO trial?
The trial investigates the effectiveness of eftilagimod alpha in combination with radiotherapy and KEYTRUDA for treating soft tissue sarcoma.
When will the results of the trial be presented?
The results will be presented on November 13 at the CTOS Annual Meeting.
How does Immutep contribute to cancer treatment advances?
Immutep specializes in developing therapies that target immune response mechanisms, particularly focusing on LAG-3.
Who is Dr. Pawel Sobczuk?
Dr. Sobczuk is a leading researcher in the field of soft tissue sarcoma and will present the trial data at the conference.
Where can I find more information about Immutep's initiatives?
For more information, please visit the Immutep website, which provides updates on ongoing research and therapy developments.
